Literature DB >> 17205454

The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients.

Barbara H McGovern1, Yoav Golan, Marvin Lopez, Daniel Pratt, Angela Lawton, Grayson Moore, Mark Epstein, Tamsin A Knox.   

Abstract

BACKGROUND: Studies of the progression liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus-coinfected patients suggest that cirrhosis is associated with immunosuppression, as measured by low absolute CD4(+) T cell counts. However, we hypothesized that, in patients with advanced liver disease, low CD4(+) T cell counts may occur secondary to portal hypertension and splenic sequestration, regardless of the presence or absence of HIV infection.
METHODS: Sixty HIV-seronegative outpatients with cirrhosis were enrolled during the period 2001-2003 in a prospective, cross-sectional study of the association between liver disease and CD4(+) T cell counts and percentages. Demographic characteristics, liver disease-related characteristics, and laboratory results--including CD4(+) T cell parameters--were collected.
RESULTS: A total of 39 patients (65%) had a low CD4(+) T cell count; 26 patients (43%) and 4 patients (7%) had CD4(+) T cell counts <350 and <200 cells/mm(3), respectively. Abnormal CD4(+) T cell counts were associated with splenomegaly (P=.03), thrombocytopenia (P=.002), and leukopenia (P<.001). The percentage of CD4(+) T cells was normal in 95% of patients who had a low absolute CD4(+) T cell count. CD4(+) T cell counts were significantly lower among cirrhotic patients than among 7638 HIV-seronegative historic control subjects without liver disease.
CONCLUSIONS: Cirrhosis is associated with low CD4(+) T cell counts in the absence of HIV infection. Discordance between low absolute CD4(+) T cell counts and normal CD4(+) T cell percentages may be attributable to portal hypertension and splenic sequestration. Our findings have significant implications for the use and interpretation of absolute CD4(+) T cell counts in HIV-infected patients with advanced liver disease.

Entities:  

Mesh:

Year:  2006        PMID: 17205454     DOI: 10.1086/509580

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

1.  Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples.

Authors:  Richard K Sterling; Jacob A Wegelin; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Puneet Puri; Mitchell L Shiffman; Melissa A Contos; A Scott Mills; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2010-08-20       Impact factor: 11.382

2.  Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Authors:  Vincent Lo Re; Craig W Newcomb; Dena M Carbonari; Jason A Roy; Keri N Althoff; Mari M Kitahata; K Rajender Reddy; Joseph K Lim; Michael J Silverberg; Angel M Mayor; Michael A Horberg; Edward R Cachay; Gregory D Kirk; Mark Hull; John Gill; Timothy R Sterling; Jay R Kostman; Marion G Peters; Richard D Moore; Marina B Klein; H Nina Kim
Journal:  J Acquir Immune Defic Syndr       Date:  2019-09-01       Impact factor: 3.731

3.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

4.  Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection.

Authors:  Nicole L Yonkers; Scott Sieg; Benigno Rodriguez; Donald D Anthony
Journal:  J Infect Dis       Date:  2011-01-10       Impact factor: 5.226

Review 5.  Adding fuel to the fire: alcohol's effect on the HIV epidemic in Sub-Saharan Africa.

Authors:  Judith A Hahn; Sarah E Woolf-King; Winnie Muyindike
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

6.  Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.

Authors:  Lars I Gjærde; Leah Shepherd; Elzbieta Jablonowska; Adriano Lazzarin; Mathieu Rougemont; Katharine Darling; Manuel Battegay; Dominique Braun; Valerie Martel-Laferriere; Jens D Lundgren; Jürgen K Rockstroh; John Gill; Andri Rauch; Amanda Mocroft; Marina B Klein; Lars Peters
Journal:  Clin Infect Dis       Date:  2016-06-15       Impact factor: 9.079

7.  Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.

Authors:  Bevin Hearn; David Delbello; Joseph Lawler; Michel Ng; Alyson Harty; Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

8.  T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients.

Authors:  S Rashkin; S Rouster; Z D Goodman; K E Sherman
Journal:  J Viral Hepat       Date:  2009-08-26       Impact factor: 3.728

Review 9.  Evaluation and treatment of the patient coinfected with hepatitis B and HIV.

Authors:  Ellen Kitchell; Mamta K Jain
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

10.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.